Bioregenx, INC 10-K annual reports

BioRegenx, Inc. filed its 2025 10-K, reporting a 21% decrease in net sales to $1.85 million and a significant reduction in net loss to $1.54 million, while facing ongoing going concern uncertainties.

BioRegenx, Inc. files an amended 10-K to correct a transcription error in the consolidated statement of deficit, while reporting a substantial increase in net loss for the fiscal year ended December 31, 2024.

BioRegenx, Inc. reports a substantial net loss of $23.05 million for the year ended December 31, 2024, driven by decreased sales, amortization and impairment expenses.

BioRegenx, Inc., formerly Findit, Inc., released its 2023 annual report, detailing a year of significant transformation including a merger and strategic acquisitions aimed at expanding its presence in the health and wellness market.